Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring

Therapeutic Drug Monitoring

Volumn 28, Issue 4, 2006, Pages 517-525

  Rezk, Naser L ^a   Crutchley, Rustin D ^a   Yeh, Rosa F ^a   Kashuba, Angela D M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antiretroviral; Chromatography; HIV; HPLC; Nonnucleoside reverse transcriptase inhibitor; Protease inhibitor; Therapeutic drug monitoring

Indexed keywords

AMPRENAVIR; ATAZANAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR;

ANALYTIC METHOD; ARTICLE; DIAGNOSTIC ACCURACY; DRUG DETERMINATION; DRUG ISOLATION; DRUG MONITORING; DRUG STRUCTURE; ELUTION; FOOD AND DRUG ADMINISTRATION; GOOD LABORATORY PRACTICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; PRIORITY JOURNAL; VALIDATION STUDY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; DRUG STABILITY; HIV PROTEASE INHIBITORS; HUMANS; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PYRIDINES; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SOLUTIONS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 33746857303     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200608000-00006     Document Type: Article

References (16)

1. Drusano GL, Bilello JA, Preston SL, et al. Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J Infect Dis. 2001;183:1126-1129.
2. Gong YF, Robinson BS, Rose RE, et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother. 2000;44:2319-2326.
3. Robinson BS, Riccardi KA, Gong YF, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother. 2000;44:2093-2099.
4. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
5. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med. 2001;344:984-996.
6. The US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. October 10, 2005. Available at: http://aidsinfo.nih.gov/Guidelines. Accessed December 20, 2005.
7. Falloon J, Piscitelli S, Vogel S, et al. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis. 2000;30:313-318.
8. Cateau E, Tournier N, Dupuis A, et al. Determination of atazanavir in human plasma using solid-phase extraction and high-performance liquid chromatography. J Pharm Biomed Anal. 2005;39:791-795.
9. Crommentuyn KM, Rosing H, Hillebrand MJ, et al. Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;804:359-367.
10. Schuster A, Burzawa S, Jemal M, et al. Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;788:377-386.
11. Rezk NL, Tidwell RR, Kashuba AD. High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;805:241-247.
12. Shabir GA. Validation of high-performance liquid chromatography methods for pharmaceutical analysis. Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. J Chromatogr A. 2003;987:57-66.
13. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm Res. 2000;17:1551-1557.
14. Droste JA, Aarnoutse RE, Koopmans PP, et al. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr. 2003;32:287-291.
15. Holland DT, DiFrancesco R, Stone J, et al. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004;48:824-831.
16. Dailly E, Raffi F, Jolliet P. Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;813:353-358.